Physician profile
Paul L Underwood
NPI 1588665681
$258,743.35
in general payments reported to CMS, 2019-2025
14 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2021: $475 · 2022: $290 · 2023: $17K · 2024: $106K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $253K · Food and Beverage: $2,554 · Travel and Lodging: $2,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $252,500.00 |
| Food and Beverage | $2,553.86 |
| Travel and Lodging | $2,426.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $244,640.58 | 2023-2025 | Clinical Trial Product |
| Alnylam Pharmaceuticals INC. | $10,920.71 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $1,228.82 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $441.95 | 2019-2025 | Enhertu |
| Medtronic, INC. | $280.84 | 2023-2025 | Synchromedii, Intellis Adaptivestim |
| Amgen INC. | $280.49 | 2024 | Repatha |
| Teva Pharmaceuticals USA, INC. | $224.81 | 2019-2022 | |
| Abbott Laboratories | $166.44 | 2024 | |
| Inspire Medical Systems, INC. | $144.70 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $107.55 | 2021 | |
| Rare Disease Therapeutics, INC. | $96.84 | 2019 | |
| Asahi Intecc USA, INC. | $92.08 | 2025 | Asahi Interventional Radiology Wires |
| Medtronic Vascular, INC. | $83.78 | 2019 | |
| Penumbra, INC. | $33.76 | 2025 | Indigo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Underwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.